Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118480 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL117739 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL650656 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118129 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297784 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL23921985 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL375162 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297783 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118128 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL2801944 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360330-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2020-11-19 | — | — | US | claimed |
| EP-2542060-B1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IE LTD (IE) | 2019-10-02 | — | — | EP | claimed |
| US-20170128406-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2017-05-11 | — | — | US | claimed |
| US-20150335607-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2015-11-26 | — | — | US | claimed |
| EP-3196280-B1 | COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME | NISSUI CORP (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20240352462-A1 | ANTISENSE INHIBITORS OF MIR17HG PRE-RNA AS THERAPEUTIC AGENTS IN CANCER | DANA FARBER CANCER INST INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4441227-A2 | ANTISENSE INHIBITORS OF MIR17HG PRE-RNA AS THERAPEUTIC AGENTS IN CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240216322-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-07-04 | — | — | US | disclosed |
| US-20240016803-A1 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATIN | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-18 | — | — | US | disclosed |
| US-20230310372-A1 | CO-ADMINISTRATION OF ATORVASTATIN AND ETHYL EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-05 | — | — | US | disclosed |
| WO-2023102377-A2 | ANTISENSE INHIBITORS OF MIR17HG PRE-RNA AS THERAPEUTIC AGENTS IN CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11648229-B2 | Composition containing eicosapentaenoic acid alkyl ester, and method for producing same | NIPPON SUISAN KAISHA, LTD. (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20140213648-A1 | METHODS OF INCREASING EPA BLOOD LEVELS | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-07-31 | — | — | US | disclosed |
| US-20140186438-A1 | COMPOSITIONS COMPRISING EPA AND OBETICHOLIC ACID AND METHODS OF USE THEREOF | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187633-A1 | METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-07-03 | — | — | US | disclosed |
| US-20140142127-A1 | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils | ALMBURG, LLC (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140080850-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-3 FATTY ACID AND A HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-03-20 | — | — | US | disclosed |
| EP-2480248-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | Amarin Corporation PLC (IE) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011038122-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | AMARIN CORPORATION PLC (IE) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071176-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | AMARIN PHARMA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080850-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-3 FATTY ACID AND A HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | HMGCR, ELOVL3, FABP3 | FASN 21/4885KDM4E 2975/4885MAPT 3343/4885 |
| US-20140186438-A1 | COMPOSITIONS COMPRISING EPA AND OBETICHOLIC ACID AND METHODS OF USE THEREOF | PPARA, CPT1A, PPARG | FASN 67/4885KDM4E 1076/4885MAPT 3807/4885 |
| US-20140187633-A1 | METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS | FABP1, CPT1A, SLC10A1 | FASN 55/4885KDM4E 3000/4885MAPT 4231/4885 |
| US-20110071176-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME | HMGCR, ELOVL3, SCD | FASN 21/4885KDM4E 2890/4885MAPT 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.